» Articles » PMID: 36679916

Mortality and Associated Factors in Patients with COVID-19: Cross-Sectional Study

Abstract

The novel virus severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is highly virulent and causes coronavirus disease 2019 (COVID-19), resulting in high morbidity and mortality mainly associated with pulmonary complications. Because this virus is highly transmissible, it was quickly spread globally, resulting in COVID-19 being declared as a pandemic. This study aimed to analyze the prevalence of mortality and the factors related to mortality due to COVID-19 in patients with severe acute respiratory syndrome (SARS) at a university hospital in the Central—West region of Brazil. This retrospective cross-sectional study was based on an analysis of the medical records of patients with SARS aged >18 years and admitted to an intensive care unit due to COVID-19 with the requirement of invasive mechanical ventilation. Hospital death was considered as an outcome variable in this study. Moreover, demographic and lifestyle-related variables as well as the therapeutic measures used during the hospital stay were recorded and correlated with the death outcome. After excluding 188 medical records, 397 were analyzed. Most of the participants were men (59.7%), and the mortality rate in patients with SARS due to COVID-19 was 46.1%. Multiple regression analysis indicated that the independent factors associated with mortality in patients with SARS due to COVID-19 were the age of >60 years (p < 0.001) and the use of azithromycin (p = 0.012). Protective factors for mortality were considered as not having the following diseases: hyperthyroidism, asthma, hepatic inheritance, and not being a smoker. The mortality rate in patients with SARS due to COVID-19 was associated with older age and the use of azithromycin.

Citing Articles

Thyroid dysfunction in the wake of Omicron: understanding its role in COVID-19 severity and mortality.

Zhang Q, Zhang Z, Liu X, Wang Y, Chen H, Hao Y Front Endocrinol (Lausanne). 2024; 15:1412320.

PMID: 39081794 PMC: 11286428. DOI: 10.3389/fendo.2024.1412320.


Significant association between asthma and a lower risk of mortality among COVID-19 patients in Spain: A meta-analysis.

Shi L, Han X, Wang Y, Xu J, Yang H Qatar Med J. 2024; 2024(3):34.

PMID: 39040991 PMC: 11262156. DOI: 10.5339/qmj.2024.34.


Clinical-laboratory characteristics predictive of COVID-19 severity: a prospective hospital cohort, in Pernambuco, Northeast Brazil.

Brito C, Mariz C, Franca R, Lopes E, Silva L, Neto R Braz J Microbiol. 2024; 55(3):2643-2654.

PMID: 38955981 PMC: 11405567. DOI: 10.1007/s42770-024-01382-2.


A Meta-Analysis on the Association between Peptic Ulcer Disease and COVID-19 Severity.

Wang Y, Xu J, Shi L, Yang H, Wang Y Vaccines (Basel). 2023; 11(6).

PMID: 37376476 PMC: 10304706. DOI: 10.3390/vaccines11061087.


Necrotizing Skin and Soft Tissue Infection after Gluteal Augmentation in a Perioperatively Asymptomatic COVID-19 Patient-Complications of the Post-Lockdown Era? A Case Report.

Stojicic M, Jurisic M, Marinkovic M, Jovanovic M, Igic A, Nikolic Zivanovic M Medicina (Kaunas). 2023; 59(5).

PMID: 37241146 PMC: 10221377. DOI: 10.3390/medicina59050914.

References
1.
Castro A, Moreira M, De Souza Bermejo P, Rodrigues W, Prata D . Mortality and Years of Potential Life Lost Due to COVID-19 in Brazil. Int J Environ Res Public Health. 2021; 18(14). PMC: 8305074. DOI: 10.3390/ijerph18147626. View

2.
Funakoshi K, Morita T, Kumanogoh A . Longer Prehospitalization and Preintubation Periods in Intubated Non-survivors and ECMO Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021; 8:727101. PMC: 8554002. DOI: 10.3389/fmed.2021.727101. View

3.
Theoharides T, Conti P . Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents. 2020; 34(3):1241-1243. DOI: 10.23812/20-EDITORIAL_1-5. View

4.
Amawi H, Deiab G, Aljabali A, Dua K, Tambuwala M . COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv. 2020; 11(4):245-268. PMC: 7222554. DOI: 10.4155/tde-2020-0035. View

5.
Oldenburg C, Pinsky B, Brogdon J, Chen C, Ruder K, Zhong L . Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2021; 326(6):490-498. PMC: 8285753. DOI: 10.1001/jama.2021.11517. View